Comparison of anti-PD-1/PD-L1-based regimens in relapsed/refractory diffuse large B-cell lymphoma: a meta-analysis
PeerJ · 2025
DOI: 10.7717/peerj.20314 ↗Kurz gefasst
Metaanalyse in der Zeitschrift PeerJ, 2025. Verfasst von Wenxin Jiang und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colle…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Society of Clinical Oncology-BMS Immune-Oncology Research Fund, The Chinese Society of Clinical Oncology-BMS Immune-Oncology Research Fund.
Abstract (Originalsprache)
Aim
To evaluate the therapeutic value and find out potential combination agents of programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) monoclonal antibody (mAb) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Methods
We conducted a meta-analysis to assess the efficacy and safety of PD-1/PD-L1 mAb in r/r DLBCL, potential qualified studies were searched in PubMed, Embase, Web of Science, and ClinicalTrials.gov. This meta-analysis had been registered on the PROSPERO platform (CRD42023340031).
Results
After systematic screening, a total of 32 records involving 29 studies were included, pooled survival curves indicated better progression-free survival (PFS) ( p < 0.0001; HR = 0.51, 95% CI [0.42–0.62]) and overall survival (OS) ( p = 0.013; HR = 0.71, 95% CI [0.57–0.88]) for combination therapy compared with monotherapy. Combination therapy group also achieved a better pooled complete response rate (CRR) (14.6% vs. 3.0%; p < 0.001) and overall response rate (ORR) (30.5% vs. 10.3%; p < 0.001). Analysis of the incidence of adverse events (AEs) did not demonstrate additional toxicities of combination therapy. The limitation was the predominance of single-arm trials, precluding the direct comparison of combination versus partner agents alone.
Conclusions
These findings support further exploration of PD-1/PD-L1-mAb-based combination therapy to identify long-term survival benefits, while application of monotherapy in unselected DLBCL patients is not recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Chaoyang District, Beijing, China.
Förderung
- Chinese Society of Clinical Oncology-BMS Immune-Oncology Research Fund
- The Chinese Society of Clinical Oncology-BMS Immune-Oncology Research Fund
Zitieren
APA
Jiang, W., Wen, T., & Liu, P. (2025). Comparison of anti-PD-1/PD-L1-based regimens in relapsed/refractory diffuse large B-cell lymphoma: a meta-analysis. PeerJ. https://doi.org/10.7717/peerj.20314
Vancouver
Jiang W, Wen T, Liu P. Comparison of anti-PD-1/PD-L1-based regimens in relapsed/refractory diffuse large B-cell lymphoma: a meta-analysis. PeerJ. 2025. doi:10.7717/peerj.20314
BibTeX
@article{Jiang2025,
author = {Jiang, Wenxin and Wen, Tingyu and Liu, Peng},
title = {Comparison of anti-PD-1/PD-L1-based regimens in relapsed/refractory diffuse large B-cell lymphoma: a meta-analysis},
journal = {PeerJ},
year = {2025},
doi = {10.7717/peerj.20314}
}
EUVIMED